The result showed that the methylation of FGFR2 was upregulated in most cancer types including LUSC, thyroid carcinoma (THCA), bladder urothelial carcinoma (BLCA), pancreatic adenocarcinoma (PAAD), KIRP, head and neck squamous cell carcinoma (HNSC), lung adenocarcinoma (LUAD), KIRC, esophageal carcinoma (ESCA), COAD, and PRAD (Figure 1B). This evidence concerns the gene FGFR2 and prostate adenocarcinoma.